Neutrophils in oncolytic virus immunotherapy
2024

Neutrophils in Oncolytic Virus Immunotherapy

Sample size: 3233 publication 10 minutes Evidence: moderate

Author Information

Author(s): Zhou Danya, Zhang Chenglin, Sun Jingyi, Yuan Ming

Primary Institution: The First Affiliated Hospital of Anhui Medical University

Hypothesis

What is the role of neutrophils in oncolytic virus therapy for cancer treatment?

Conclusion

Neutrophils play a dual role in oncolytic virus therapy, both enhancing antiviral responses and potentially inhibiting the efficacy of the therapy.

Supporting Evidence

  • Neutrophils constitute approximately 50% to 70% of human peripheral blood leukocytes.
  • Patients with low neutrophil-to-lymphocyte ratio before treatment had significantly longer overall survival.
  • Neutrophils can phagocytize viruses and release antiviral peptides.

Takeaway

Neutrophils are important immune cells that help fight infections and can also affect cancer treatments using special viruses that target tumors.

Methodology

This review summarizes existing literature on the role of neutrophils in various oncolytic virus therapies.

Potential Biases

Potential bias due to the focus on neutrophils while other immune cells may also play significant roles.

Limitations

Limited research on the specific interactions between neutrophils and oncolytic viruses.

Participant Demographics

Patients receiving oncolytic virotherapy from 2000 to 2020.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.3389/fimmu.2024.1490414

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication